ArticleJournal of Korean medical science2026
Trends in Atypical Antipsychotic Use Among Children and Adolescents With Depressive Disorders in Korea.
Article in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Treatment patterns and comparative clinical outcomes of ADHD medications in adolescents and young adults with comorbid major depressive disorder.Journal of affective disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAtypical antipsychotics (AAPs) are increasingly prescribed to children and adolescents. Most AAPs are prescribed off-label for children and adolescents with depressive disorders. We investigated the longitudinal trends and patterns of AAP prescription in Korean children and adolescents with depressive disorders.
methodsWe conducted a population-based study using data from the Korean National Health Insurance Review and Assessment Service to assess AAP prescriptions among Koreans aged 0-18 years with depressive disorders between 2010 and 2022. An annual cross-sectional assessment was used to analyze longitudinal trends. Additionally, we focused on the most recent year (2022) to assess the current prescription patterns of AAP.
resultsThe annual proportion of AAP prescriptions among children and adolescents with depressive disorders will increase from 10.4% in 2010 to 40.0% in 2022 (average annual percentage change: 14.9; 95% confidence interval, 14.3 to 16.3). This trend was more pronounced in patients with depressive disorders with psychiatric comorbidities than in those without psychiatric comorbidities. Over the last 13 years, the predominantly prescribed AAPs have shifted from risperidone to aripiprazole. According to recent data (2022), the most-prescribed AAP for children and adolescents with depressive disorders was aripiprazole, followed by risperidone, quetiapine, and olanzapine. Children and adolescents with depressive disorders and psychiatric comorbidities, particularly Attention-Deficit Hyperactivity Disorder, were more frequently prescribed AAPs (
conclusionThe use of AAPs has progressively increased among Korean children and adolescents with depressive disorders, particularly among those with psychiatric comorbidities. Further studies are needed to establish safer and more evidence-based AAP treatments for depressive disorders in children and adolescents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.